Skip to main content

Notification of Drug Policy Revisions Effective January 1, 2023 (Posted October 17, 2022)

Policy Name

Revised Criteria

Infliximab (Remicade®) and Infliximab Biosimilars 

 

Changed requirement for trial and failure of preferred agents to include two agents: Avsola and Inflectra. Adjusted non-preferred agents to include Remicade and Infliximab. Policy notification given 10/17/2022 for effective date 1/1/2023.